Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "Tetrahydrocannabinolic acid" patented technology

Tetrahydrocannabinolic acid (THCA, 2-COOH-THC; conjugate base tetrahydrocannabinolate) is a precursor of tetrahydrocannabinol (THC), the active component of cannabis. THCA is found in variable quantities in fresh, undried cannabis, but is progressively decarboxylated to THC with drying, and especially under intense heating such as when cannabis is smoked or cooked into cannabis edibles. THCA is often the majority constituent in cannabis resin concentrates, such as hashish and hash oil, when prepared from high-THC cannabis plant material, frequently comprising between 50% and 90% by weight.

Cannabis plant isolate comprising delta-9-tetrahydrocannabinol and a method for preparing such an isolate

InactiveUS20150126754A1High purityHigh yieldNervous disorderOrganic chemistryDelta-9-tetrahydrocannabinolSolvent
The present invention relates to a method for preparing a Cannabis plant Δ9-tetrahydrocannabinol isolate from a crude solvent extract of Cannabis plant material. The invention relates further to a Cannabis plant THC isolate comprising Δ9-tetrahydrocannabinol, Cannabinol (CBN) and / or Cannabidiol (CBD) and to a pharmaceutical composition comprising the Cannabis plant THC isolate.
Owner:ECHO PHARM BV (NL)

Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery

ActiveUS20110092583A1Easy to transportPromote lymphatic transportBiocideSenses disorderChylomicronCytochrome P450
Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and / or mixed glycerides and / or free fatty acids containing medium and / or long chain saturated, mono-unsaturated, and / or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron / lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic / non-amphiphilic solutes to induce semi-solid formation for targeted release rates.
Owner:MURTY RAM B +1

Methods for making compositions and compositions for treating pain and cachexia

InactiveUS20080103193A1Avoiding high first metabolismHighly psychoactiveBiocideOrganic chemistryΔ9-tetrahydrocannabinolPharmacology
The present invention pertains to methods for making compositions and compositions for treating pain and cachexia or AIDS wasting. In particular, the instant invention employs methods for making Δ9-tetrahydrocannabinol (Δ9-THC) and Δ9-tetrahydrocannabinolic acid (Δ9-THCA) from Cannabis sativa, and compositions for the treatment of these diseases.
Owner:CASTOR TREVOR PERCIVAL +3

Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

ActiveUS20170008868A1Low selectivityLow yieldNervous disorderOrganic chemistryDelta-9-tetrahydrocannabinolAcid catalyzed
The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
Owner:PURISYS LLC

Parenteral formulations

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
Owner:GW RES LTD

Methods for Extraction and Isolation of Isoprenoid and Terpene Compounds from Biological Extracts

ActiveUS20180344785A1Rapidly cost-effectively extractedOrganic active ingredientsMagnoliophyta medical ingredientsCannabisPrenylation
A method for the extraction and isolation of the terpene and isoprenoid compounds from plant material, followed by a centrifugal force induced selective crystallization of isoprenoids resulting in a separation of terpene and isoprenoid fractions. This this method is suitable for the extraction of cannabinoids from Cannabis and the enrichment tetrahydrocannabinolic acid and reduction of tetrahydrocannabinol in an extract.
Owner:CONCENTRATED CONSULTING GRP LLC

Methods for Purification of Non-Psychoactive Isoprenoid Compounds from Biological Extracts

A method for the extraction and isolation of the terpene and isoprenoid compounds from plant material, followed by a centrifugal force induced selective crystallization of isoprenoids resulting in a separation of terpene and isoprenoid fractions. This this method is suitable for the extraction of cannabinoids from Cannabis and the enrichment tetrahydrocannabinolic acid and reduction of tetrahydrocannabinol in an extract. The purity of tetrahydrocannabinolic acid resulting from centrifugal crystallization is such that dissolution and selective recrystallization of tetrahydrocannabinolic acid is possible resulting in >99.9% pure tetrahydrocannabinolic acid, w / w.
Owner:CONCENTRATED CONSULTING GRP LLC

Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
Owner:NORAMCO INC

Methods for purification of non-psychoactive isoprenoid compounds from biological extracts

A method for the extraction and isolation of the terpene and isoprenoid compounds from plant material, followed by a centrifugal force induced selective crystallization of isoprenoids resulting in a separation of terpene and isoprenoid fractions. This this method is suitable for the extraction of cannabinoids from Cannabis and the enrichment tetrahydrocannabinolic acid and reduction of tetrahydrocannabinol in an extract. The purity of tetrahydrocannabinolic acid resulting from centrifugal crystallization is such that dissolution and selective recrystallization of tetrahydrocannabinolic acid is possible resulting in >99.9% pure tetrahydrocannabinolic acid, w / w.
Owner:CONCENTRATED CONSULTING GRP LLC

Parenteral formulations

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
Owner:GW RES LTD

Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent

A stable composition for rapid delivery by inhalation to the lungs, and subsequently to the bloodstream, is provided. The composition comprises a therapeutically effective amount of delta-9-tetrahydrocannabinol in a pharmaceutically-acceptable semiaqueous solvent comprising an alcohol, water and a glycol. A composition comprising volumetric ratios of ethanol:water:propylene glycol selected from those in the range of from 10-70:10-30:20-80, respectively, having a combined total of 100 is also provided. A sterile and / or preserved sealed unit-or multi-unit dosage form of delta-9-tetrahydrocannabinol is further provided.
Owner:ALKEM LAB LTD

Encapsulated cannabinoid formulations for transdermal delivery

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.
Owner:NUTRAE LLC

Method for detecting five cannabinol compounds in cannabis oil by utilizing HPLC method

The invention belongs to the field of analytical chemistry, and relates to a method for detecting five cannabinol compounds in cannabis oil by high performance liquid chromatography (HPLC). According to the method, a C18 chromatographic column is adopted, ultrapure water is used as a mobile phase A, acetonitrile is used as a mobile phase B for gradient elution, and a sample enters a detector for detection. The cannabinol compounds are delta 9-tetrahydrocannabinol, cannabidiol, cannabinol, tetrahydrocannabinolic acid and cannabidiolic acid. The technical scheme provided by the invention can lay a methodological foundation for the establishment of related detection method standards, and has important meanings for preventing cannabis oil with overproof cannabinol content from flowing into the market and promoting the effective supervision of industrial cannabis food at home and abroad.
Owner:CHINA NAT INST OF STANDARDIZATION

Method for simultaneously detecting five cannabinol compounds by using HPLC-MS/MS

The invention belongs to the field of analytical chemistry, and particularly relates to a method for simultaneously detecting five cannabinol compounds by using a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS). According to the method, a special chromatographic column for cannabinol is adopted, a formic acid aqueous solution is used as a mobile phase A, acetonitrile is used as a mobile phase B for gradient elution, and a sample enters a detector for detection. The cannabinol compound is tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabinol (CBN), cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC). The method is high in detection sensitivity, good in recovery rate and easy to operate.
Owner:CHINA NAT INST OF STANDARDIZATION

Encapsulated cannabinoid formulations for oral delivery

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as Cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. These preparations demonstrates the viability of sublingual, buccal, or oral delivery using an aqueous-based encapsulation method, including as a beverage or drink.
Owner:NUTRAE LLC

Microorganisms and Methods for the Fermentation of Cannabinoids

Disclosed herein are microorganism and methods that can be used for the synthesis of cannabigerolic acid (CBGA) and cannabinoids. The methods disclosed can be used to produce CBGA, Δ9-tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabichromene (CBC). Enzymes useful for the synthesis of CBGA and cannabinoids, include but are not limited to acyl activating enzyme (AAE1), polyketide synthase (PKS), olivetolic acid cyclase (OAC), prenyltransferase (PT), THCA synthase (THCAS), CBDA synthase (CBDAS), CBCA synthase (CBCAS), HMG-Co reductase (HMG1), and / or farnesyl pyrophosphate synthetase (ERG20). The microorganisms can also have one or more genes disrupted, such as gene that that controls beta oxidation of long chain fatty acids.
Owner:ELESZTO GENETIKA INC

Compositions and methods for treating cancer

A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a Cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a Cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises Cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises Cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.
Owner:MOR RES APPL LTD +1

Compositions and methods for treating inflammatory diseases

A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.
Owner:MOR RES APPL LTD +1

Complete animal food having cannabinoids in trace concentrations to avoid toxicity

A nutritionally complete animal food including, vitamins, and minerals to sustain the animal's health and wellness. The one or more ingredients containing cannabinoids added to the nutritionally complete animal food at the time of manufacturing. These cannabinoids are selected from the group consisting of Cannabichromenic acid (CBCA), Cannabidiolic acid (CBDA), Cannabidivarinic acid (CBDVA), Cannabigerolic acid (CBGA), Cannabinolic acid (CBNA), Δ9-Tetrahydrocannabinolic acid (THCA),Tetrahydrocannabinolic acid (THCVA) and combinations thereof. The concentrations of each of the cannabinoids are each less than 100 parts per million (ppm) in the at least one ingredient. In an alternate embodiment, the one or more ingredients have cannabinoids include in an aggregate concentration of less than 100 parts per million (ppm).
Owner:HIGH PLAINS NUTRITION LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products